2-Bromo-1-(4-octylphenyl)-ethanone - CAS 64068-76-4
Catalog: |
BB055411 |
Product Name: |
2-Bromo-1-(4-octylphenyl)-ethanone |
CAS: |
64068-76-4 |
Synonyms: |
2-bromo-1-(4-octylphenyl)ethanone; 2-bromo-4'-octylacetophenone; 1-(4-Octylphenyl)-2-bromoethanone; 2-Bromo-1-(4octyl-phenyl)-ethanone; 2-Bromo-1-(4-octyl-phenyl)-ethanone |
IUPAC Name: | 2-bromo-1-(4-octylphenyl)ethanone |
Molecular Weight: | 311.26 |
Molecular Formula: | C16H23BrO |
Canonical SMILES: | CCCCCCCCC1=CC=C(C=C1)C(=O)CBr |
InChI: | InChI=1S/C16H23BrO/c1-2-3-4-5-6-7-8-14-9-11-15(12-10-14)16(18)13-17/h9-12H,2-8,13H2,1H3 |
InChI Key: | OEFKRBPTEVTSLY-UHFFFAOYSA-N |
GHS Hazard Statement: | H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation] |
Precautionary Statement: | P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
CN-110963935-A | 1-phenyl-2-aminoacetophenone derivative and medical application thereof | 20180930 |
HU-230806-B1 | Process for the preparation of fingolimod hydrochloride | 20151215 |
WO-2014111949-A1 | Intermediates and process for the preparation of high purity fingolimod hydrochloride | 20130121 |
AU-2012298567-A1 | New ligands for targeting of S1P receptors for in vivo imaging and treatment of diseases | 20110819 |
AU-2012298567-B2 | New ligands for targeting of S1P receptors for in vivo imaging and treatment of diseases | 20110819 |
EP-2744776-A1 | New ligands for targeting of s1p receptors for in vivo imaging and treatment of diseases | 20110819 |
US-2014170067-A1 | New ligands for targeting of s1p receptors for in vivo imaging and treatment of diseases | 20110819 |
US-9345791-B2 | Ligands for targeting of S1P receptors for in vivo imaging and treatment of diseases | 20110819 |
WO-2013026765-A1 | New ligands for targeting of s1p receptors for in vivo imaging and treatment of diseases | 20110819 |
EP-2896609-A1 | Crystalline fingolimod citrate for the treatment of relapsing-remitting multiple sclerosis | 20090724 |
Complexity: | 219 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 310.09323 |
Formal Charge: | 0 |
Heavy Atom Count: | 18 |
Hydrogen Bond Acceptor Count: | 1 |
Hydrogen Bond Donor Count: | 0 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 310.09323 |
Rotatable Bond Count: | 9 |
Topological Polar Surface Area: | 17.1Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 6.4 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS